Edition:
United Kingdom

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.72USD
15 Dec 2017
Change (% chg)

$0.51 (+3.35%)
Prev Close
$15.21
Open
$15.23
Day's High
$15.73
Day's Low
$15.09
Volume
935,845
Avg. Vol
380,191
52-wk High
$19.94
52-wk Low
$13.44

Select another date:

Mon, Dec 4 2017

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2h08KF7) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company

FDA approves Ironwood Pharma's gout drug

Aug 21 Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout.

BRIEF-Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout

* Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout

BRIEF-Ironwood Pharmaceuticals Q2 loss per share $0.30

* Ironwood Pharmaceuticals provides second quarter 2017 investor update

Ironwood reflux drug appears effective, safe in midstage trial

Ironwood Pharmaceuticals Inc said on Thursday its potential blockbuster drug for gastroesophageal reflux disease (GERD) not controlled by current medicines significantly reduced heartburn severity and regurgitation frequency, meeting the main goals of a midstage trial.

Ironwood reflux drug appears effective, safe in midstage trial

July 20 Ironwood Pharmaceuticals Inc said on Thursday its potential blockbuster drug for gastroesophageal reflux disease (GERD) not controlled by current medicines significantly reduced heartburn severity and regurgitation frequency, meeting the main goals of a midstage trial.

Select another date: